{
  "success": true,
  "sourceFile": "input/Alexion_NCT04573309_Wilsons_SAP.pdf",
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33
  ],
  "modelUsed": "gemini-2.5-pro",
  "sapData": {
    "analysisPopulations": [
      {
        "id": "pop_1",
        "name": "Screened Set",
        "populationType": "Other",
        "instanceType": "AnalysisPopulation",
        "description": "The Screened Set will include all participants who signed an informed consent form (ICF).",
        "criteria": "Signed an informed consent form"
      },
      {
        "id": "pop_2",
        "name": "Enrolled Set",
        "populationType": "Other",
        "instanceType": "AnalysisPopulation",
        "description": "The Enrolled Set will include all participants who were enrolled in the study.",
        "criteria": "Enrolled in the study"
      },
      {
        "id": "pop_3",
        "name": "Full Analysis Set",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "FA Set",
        "description": "The Full Analysis (FA) Set will include all participants who were enrolled and received at least 1 dose of study drug. The FA Set will be the primary population for all efficacy analyses.",
        "criteria": "Enrolled and received at least 1 dose of study drug"
      },
      {
        "id": "pop_4",
        "name": "Per Protocol Set",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "PP Set",
        "description": "The Per Protocol (PP) Set will include all participants in the FA Set who are compliant with the protocol and do not have any major protocol deviations that would impact the interpretability of the primary efficacy endpoint data. The specific criteria for the PP Set will be defined and finalized prior to database lock. The PP Set will be used for sensitivity analyses of the primary efficacy endpoint.",
        "criteria": "In FA Set, compliant with protocol, and no major protocol deviations impacting primary efficacy endpoint"
      },
      {
        "id": "pop_5",
        "name": "Safety Set",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "description": "The Safety Set will include all participants who received at least 1 dose of study drug. The Safety Set will be the primary population for all safety analyses.",
        "criteria": "Received at least 1 dose of study drug"
      },
      {
        "id": "pop_6",
        "name": "Pharmacokinetic Analysis Set",
        "populationType": "PK",
        "instanceType": "AnalysisPopulation",
        "label": "PK Analysis Set",
        "description": "The Pharmacokinetic (PK) Analysis Set will include all participants in the Safety Set who have sufficient plasma concentration data to allow for the derivation of at least 1 PK parameter. The PK Analysis Set will be used for all PK analyses.",
        "criteria": "In Safety Set with sufficient plasma concentration data to derive at least 1 PK parameter"
      },
      {
        "id": "pop_7",
        "name": "Pharmacodynamic Analysis Set",
        "populationType": "PD",
        "instanceType": "AnalysisPopulation",
        "label": "PD Analysis Set",
        "description": "The Pharmacodynamic (PD) Analysis Set will include all participants in the Safety Set who have sufficient PD data to allow for the derivation of at least 1 PD parameter. The PD Analysis Set will be used for all PD analyses.",
        "criteria": "In Safety Set with sufficient PD data to derive at least 1 PD parameter"
      }
    ],
    "characteristics": [
      {
        "id": "char_1",
        "name": "Age",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Age of the participant."
      },
      {
        "id": "char_2",
        "name": "Sex",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Sex of the participant."
      },
      {
        "id": "char_3",
        "name": "Race",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Race of the participant."
      },
      {
        "id": "char_4",
        "name": "Ethnicity",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Ethnicity of the participant."
      },
      {
        "id": "char_5",
        "name": "Height",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Height at baseline."
      },
      {
        "id": "char_6",
        "name": "Weight",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Weight at baseline."
      },
      {
        "id": "char_7",
        "name": "Body Mass Index (BMI)",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Body Mass Index at baseline."
      },
      {
        "id": "char_8",
        "name": "Age at diagnosis of Wilson Disease",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Age at diagnosis of Wilson Disease (WD)."
      },
      {
        "id": "char_9",
        "name": "Time since diagnosis of Wilson Disease",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Time since diagnosis of Wilson Disease (WD)."
      },
      {
        "id": "char_10",
        "name": "Wilson Disease phenotype",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Wilson Disease (WD) phenotype (neurologic, hepatic, mixed, asymptomatic)."
      },
      {
        "id": "char_11",
        "name": "Baseline laboratory values",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Baseline laboratory values including ceruloplasmin, serum copper, 24-hour urinary copper excretion, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, and international normalized ratio (INR)."
      },
      {
        "id": "char_12",
        "name": "Medical/Surgical History",
        "dataType": "Text",
        "instanceType": "Characteristic",
        "description": "Medical and surgical history coded using MedDRA."
      },
      {
        "id": "char_13",
        "name": "Wilson Disease History",
        "dataType": "Text",
        "instanceType": "Characteristic",
        "description": "Summary of Wilson Disease (WD) history."
      },
      {
        "id": "char_14",
        "name": "Prior medications used to treat Wilson Disease",
        "dataType": "Text",
        "instanceType": "Characteristic",
        "description": "Summary of prior medications used to treat Wilson Disease (WD)."
      }
    ],
    "summary": {
      "populationCount": 7,
      "characteristicCount": 14
    }
  }
}